Inpatient management of iron deficiency anemia in pediatric patients with inflammatory bowel disease: A single center experience

Table 2 Iron studies (n = 92)

		Iron therapy			P value
		No iron (n = 18)	Oral iron (n = 17)	IV iron (n = 57)
Hb (g/dL)	Admission	10.4 ± 0.2	10.0 ± 0.2	9.7 ± 0.1
(n = 92)	Follow-up	11.2 ± 0.2	10.8 ± 0.2	11.6 ± 0.1
	Change	0.8 ± 0.3a	0.8 ± 0.3a	1.9 ± 0.2b	0.003
MCV (fL)	Admission	78.8 ± 0.8	78.6 ± 0.7	78.2 ± 0.4
(n = 92)	Follow-up	80.4 ± 0.8	81.4 ± 0.8	84.2 ± 0.4
	Change	1.6 ± 1.1a	2.8 ± 1.1a	6.0 ± 0.6b	0.0004
CRP (mg/dL)	Admission	3.8 ± 0.8	3.2 ± 0.8	4.0 ± 0.4
(n = 85)	Follow-up	1.9 ± 0.9	0.8 ± 0.9	0.8 ± 0.4
	Change	-1.8 ± 1.3	-2.4 ± 1.4	-3.2 ± 0.7	0.63
ESR (mm/1h)	Admission	48 ± 5	42 ± 5	44 ± 3
(n = 80)	Follow-up	31 ± 6	23 ± 6	27 ± 3
	Change	-17 ± 8	-20 ± 8	-16 ± 4	0.94
TIBC (μg/dL)	Admission	284 ± 19	296 ± 19	301 ± 9.1
(n = 64)	Follow-up	385 ± 35	404 ± 29	323 ± 10.7
	Change	101 ± 39a	108 ± 37a	23 ± 15a	0.04
Ferritin(μg/dL)	Admission	117 ± 30	82 ± 31	79 ± 15
(n = 66)	Follow-up	70 ± 58	15 ± 54	167 ± 18
	Change	-46 ± 61a	-67 ± 61a	88 ± 23b	0.02
Iron (μg/dL)	Admission	34.5 ± 6.9	26.6 ± 6.7	23.7 ± 3.2
(n = 65)	Follow-up	45.3 ± 12.8	53.4 ± 10.6	54.0 ± 3.8
	Change	10.7 ± 13.6	26.8 ± 12.3	30.3 ± 4.9	0.41

^aP < 0.05.

^bP < 0.01.

Effects with different superscripts are statistically significant, mean ± standard error at admission, follow-up encounter, and change over time are shown. Results are from a repeated measures linear model adjusted for baseline outcome, age at admission, sex, diagnosis, baseline iron dose, and the number of days between admission and follow-up labs. After adjustment for multiple comparisons, the differences between total iron binding capacity and ferritin are not significant. Hb: Hemoglobin; MCV: Mean corpuscular volume; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; TIBC: Total iron binding capacity.